These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20099280)

  • 21. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity to previous irinotecan treatment does not predict the efficacy of combination chemotherapy with cetuximab plus irinotecan for wild-type KRAS metastatic colorectal cancer.
    Shitara K; Ura T; Matsuo K; Takahari D; Yokota T; Yuki S; Yoshida M; Utsunomiya S; Sato Y; Yamaura H; Kato M; Inaba Y; Tajika M; Kawai H; Yamazaki K; Komatsu Y; Muro K
    Eur J Cancer; 2011 Dec; 47(18):2673-80. PubMed ID: 21652203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.
    Sclafani F; Kim TY; Cunningham D; Kim TW; Tabernero J; Schmoll HJ; Roh JK; Kim SY; Park YS; Guren TK; Hawkes E; Clarke SJ; Ferry D; Frodin JE; Ayers M; Nebozhyn M; Peckitt C; Loboda A; Watkins DJ
    Int J Cancer; 2017 Jan; 140(2):431-439. PubMed ID: 27681944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
    Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.
    Moretto R; Cremolini C; Rossini D; Pietrantonio F; Battaglin F; Mennitto A; Bergamo F; Loupakis F; Marmorino F; Berenato R; Marsico VA; Caporale M; Antoniotti C; Masi G; Salvatore L; Borelli B; Fontanini G; Lonardi S; De Braud F; Falcone A
    Oncologist; 2016 Aug; 21(8):988-94. PubMed ID: 27382031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
    Licitra L; Störkel S; Kerr KM; Van Cutsem E; Pirker R; Hirsch FR; Vermorken JB; von Heydebreck A; Esser R; Celik I; Ciardiello F
    Eur J Cancer; 2013 Apr; 49(6):1161-8. PubMed ID: 23265711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
    Park SJ; Hong YS; Lee JL; Ryu MH; Chang HM; Kim KP; Ahn YC; Na YS; Jin DH; Yu CS; Kim JC; Kang YK; Kim TW
    Oncology; 2012; 82(2):83-9. PubMed ID: 22327884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
    Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
    Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
    Hörndler C; Gallego R; García-Albeniz X; Alonso-Espinaco V; Alonso V; Escudero P; Jimeno M; Ortego J; Codony-Servat J; Fernández-Martos C; Calatrava A; Marín-Aguilera M; Muñoz J; Castellví-Bel S; Castells A; Rubini M; Gascón P; Maurel J
    Cancer Biol Ther; 2011 Jan; 11(2):177-83. PubMed ID: 21099348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
    Bando H; Yoshino T; Yuki S; Shinozaki E; Nishina T; Kadowaki S; Yamazaki K; Kajiura S; Tsuchihara K; Fujii S; Yamanaka T; Ohtsu A
    Jpn J Clin Oncol; 2012 Dec; 42(12):1146-51. PubMed ID: 23071293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan.
    Fora AA; McMahon JA; Wilding G; Groman A; Ma WW; Romano KS; Fakih MG
    Oncology; 2013; 84(4):210-3. PubMed ID: 23328486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.
    Paule B; Castagne V; Picard V; Saffroy R; Adam R; Guettier C; Farinotti R; Bonhomme-Faivre L
    Med Oncol; 2010 Dec; 27(4):1066-72. PubMed ID: 19862647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
    Garcia-Albeniz X; Pericay C; Alonso-Espinaco V; Alonso V; Escudero P; Fernández-Martos C; Gallego R; Gascón P; Castellví-Bel S; Maurel J
    Tumour Biol; 2011 Apr; 32(2):417-24. PubMed ID: 21104178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
    Vincenzi B; Galluzzo S; Santini D; Rocci L; Loupakis F; Correale P; Addeo R; Zoccoli A; Napolitano A; Graziano F; Ruzzo A; Falcone A; Francini G; Dicuonzo G; Tonini G
    Ann Oncol; 2011 May; 22(5):1141-1146. PubMed ID: 21115601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
    Tímár J; Láng I
    Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
    Akiyoshi K; Yamada Y; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Taniguchi H; Furuta K
    Anticancer Res; 2013 May; 33(5):2129-34. PubMed ID: 23645765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel K-ras mutation in colorectal cancer. A case report and literature review.
    Palmirotta R; Savonarola A; Formica V; Ludovici G; Del Monte G; Roselli M; Guadagni F
    Anticancer Res; 2009 Aug; 29(8):3369-74. PubMed ID: 19661358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.